Atreca raises $125mm through Series C round

Cancer immunotherapies developer Atreca Inc. raised $125mm through an oversubscribed Series C round from investors including returning backers Wellington Management and Cormorant Asset Management; a US-based health care-focused fund, which has invested in Atreca before and led the current round; and new investors Aisling Capital, Boxer Capital (Tavistock), EcoR1 Capital, Redmile Group, Samsara BioCapital, and funds managed by Tekla Capital Management. Proceeds will help the company advance its lead candidate ATR101 into clinical trials for solid tumors including breast, lung, and colon cancers.